PFBT
CPRX

Parkside Financial Bank & Trust’s Catalyst Pharmaceutical CPRX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99.7K Buy
4,027
+889
+28% +$21.2K 0.01% 683
2025
Q4 		$73.2K Buy
3,138
+469
+18% +$10.4K 0.01% 814
2025
Q3 		$52.6K Sell
2,669
-150
-5% -$3.08K ﹤0.01% 910
2025
Q2 		$61.2K Sell
2,819
-18
-0.6% -$425 0.01% 828
2025
Q1 		$68.8K Buy
2,837
+182
+7% +$4.1K 0.01% 718
2024
Q4 		$55.4K Hold
2,655
– – 0.01% 766
2024
Q3 		$52.8K Buy
2,655
+418
+19% +$7.75K 0.01% 762
2024
Q2 		$34.7K Sell
2,237
-438
-16% -$6.82K 0.01% 870
2024
Q1 		$42.6K Buy
2,675
+812
+44% +$12.2K 0.01% 786
2023
Q4 		$31.3K Buy
+1,863
New +$25.5K 0.01% 842
2023
Q2 		– Sell
-132
Closed -$2.19K – 2029
2023
Q1 		$2.19K Hold
132
– – ﹤0.01% 1676
2022
Q4 		$2.46K Hold
132
– – ﹤0.01% 1608
2022
Q3 		$2K Buy
+132
New +$1.56K ﹤0.01% 1517

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Parkside Financial Bank & Trust's CPRX Position: Q1 2026 in Review

Parkside Financial Bank & Trust increased its Catalyst Pharmaceutical (CPRX) stake by 28% in Q1 2026, buying an estimated $21.2K and bringing the position to 4,027 shares worth $99.7K. The position accounts for 0.01% of the portfolio, ranked #683.

Parkside Financial Bank & Trust first reported a position in CPRX in Q3 2022 and has held it in 13 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Parkside Financial Bank & Trust held 4,027 shares of Catalyst Pharmaceutical worth $99.7K as of Q1 2026.
  • Parkside Financial Bank & Trust bought 889 Catalyst Pharmaceutical shares in Q1 2026, an estimated $21.2K.
  • Catalyst Pharmaceutical made up 0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #683 holding.
  • Parkside Financial Bank & Trust first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 13 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.